Oneness Biotech Co., Ltd.

4743

TW0004743000

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-15 EDT			5-day change	1st Jan Change
163.5 ^TWD	+6.17%		+7.21%	-15.94%

05-09	US FDA Agrees Oneness Biotech Co., Ltd.'s S.C. Injection Formulation of FB825 to Proceed with Phase 2 Clinical Trial to Treat Moderate-To-Severe Atopic Dermatitis	CI
04-22	Oneness Biotech Co., Ltd. Announces Plans of Phase II Clinical Trial	CI

Oneness Biotech Co., Ltd. Proposes Cash Dividends

March 16, 2023

Oneness Biotech Co., Ltd. at the AGM to be held on April 18, 2023, proposed cash dividends of TWD 0.1 per share. Total amounts of been allocated Cash dividends: TWD 39,177,285.

Latest news about Oneness Biotech Co., Ltd.

US FDA Agrees Oneness Biotech Co., Ltd.'s S.C. Injection Formulation of FB825 to Proceed with Phase 2 Clinical Trial to Treat Moderate-To-Severe Atopic Dermatitis	05-09	CI
Oneness Biotech Co., Ltd. Announces Plans of Phase II Clinical Trial	04-22	CI
Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol to Taiwan FDA for Subcutaneous Injection Formulation ofFB825 in Patients with Moderate-To-Severe Atopic Dermatitis	03-29	CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol Forsubcutaneous Injection Formulation of FB825 in Patientswith Moderate-To-Severe Atopic Dermatitis	01-30	CI
Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration	01-18	CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Oneness Biotech Co., Ltd. Announces Approval of FESPIXON	11-09	CI
Oneness Submits Medical Device Registration Application of Bonvadis for Wound Care to the Thai Food and Drug Administration in Thailand	23-10-25	CI
Oneness Biotech Co., Ltd. Submits 510(k) Application to the U.S. FDA to Expand the Intended Patient Population and Add Multiple Chronic Wound Indications for Bonvadis	23-08-31	CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Oneness Biotech Co., Ltd. Obtains Import License for Bonvadis, The Wound Care Topical Cream in South Africa	23-08-09	CI
Oneness Biotech Co., Ltd. Announces Submission of Registration Application for Bonvadis, the Wound Care Topical Cream to the Drug Regulatory Authority of Pakistan	23-08-04	CI
US FDA agrees to proceed with Phase 2 clinical trial for SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio	23-08-02	CI
Oneness Biotech Co., Ltd. Receives Approval from Malaysia NPRA for FESPIXON, the New Drug in Treatment of Diabetic Footulcers	23-07-14	CI
Oneness Biotech Co., Ltd. Announces the National Agency of Drug and Food Control Accepts the NDA Application of the Diabetic Foot Ulcer New Drug, Fespixon	23-06-06	CI
Oneness Biotech Co., Ltd. Submits IND to US FDA for a Phase II Clinical Trial on the Broad-Spectrum Anti-SARS-CoV-2siRNA Co-Developed with Microbio	23-05-31	CI
Oneness Biotech Co., Ltd. Announces Cash Dividend, Payable on July 21, 2023	23-05-30	CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Oneness and Microbio Co., Ltd. Announces the Phase 1 Clinical Trial Data of Sns812	23-04-28	CI
Oneness Announces Bonvadis Cream for Scar Management Has Been Granted Import License in Europe	23-04-27	CI
Oneness Receives Medical Devices Export License Approvals by TFDA on Bonvadis Topical Cream and Bonvadis Cream	23-03-22	CI
Oneness Biotech Co., Ltd. Proposes Cash Dividends	23-03-16	CI
Oneness Biotech Co., Ltd. Obtains Import License in New Zealand	23-03-14	CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-07	CI

Chart Oneness Biotech Co., Ltd.

Duration

Period

More charts

ONENESS BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the research, development, production and sales of health products. The Company's main products include health supplies, health food and healthy food. The Company is also involved in the development of new drugs for the treatment of wound healing in chronic diabetic foot ulcers, as well as the development of new anticancer drugs. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Oneness Biotech Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

163.5 TWD

Average target price

262 TWD

Spread / Average Target

+60.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ONENESS BIOTECH CO., LTD.	-15.94%	2.31B
ELI LILLY AND COMPANY	+32.36%	694B
NOVO NORDISK A/S	+29.82%	593B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.45%	239B
ROCHE HOLDING AG	-3.31%	209B
NOVARTIS AG	+10.10%	209B
AMGEN INC.	+9.27%	169B

Other Pharmaceuticals